Amy Burroughs, Terns Pharmaceuticals CEO
September 9, 2024 07:08 AM EDTUpdated 02:26 PM
R&D

Terns’ oral GLP-1 pass­es Phase 1 test with promis­ing weight loss af­ter one month

Ayisha Sharma

News Reporter

Terns Phar­ma­ceu­ti­cals un­veiled ear­ly-phase weight loss da­ta from an oral GLP-1 ag­o­nist that it says could be more tol­er­a­ble at high­er dos­es than cur­rent­ly mar­ket­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

FDA tells on­col­o­gy com­pa­nies how to run mul­ti-re­gion­al can­cer tri­als with a US ap­proval in mind

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times